Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10033011 | 0.82 | MEN1 (0.52) | KMT2AMEN1LMNACYP1A2MAPT | |
| SCHEMBL1095103 | 0.81 | SMN1; SMN2 (0.56) | KMT2AMEN1TDP1MAPTPOLB | |
| SCHEMBL14477221 | 0.80 | EPHX1 (0.41) | KMT2AMEN1TDP1LMNACYP1A2 | |
| SCHEMBL24327752 | 0.80 | FFAR1 (0.47) | KMT2AMEN1LMNAPOLBEPHX1 | |
| SCHEMBL10355170 | 0.80 | ESR1 (0.44) | KMT2ATDP1LMNACYP1A2MAPT | |
| SCHEMBL2553482 | 0.79 | PPARA (0.49) | LMNACYP1A2POLBALDH1A1CYP3A4 | |
| SCHEMBL6504745 | 0.79 | PPARA (0.49) | LMNACYP1A2POLBALDH1A1CYP3A4 | |
| SCHEMBL17653645 | 0.79 | PPARA (0.49) | LMNACYP1A2POLBALDH1A1CYP3A4 | |
| SCHEMBL24327731 | 0.78 | HPGD (0.49) | KMT2AMEN1LMNACYP1A2MAPT | |
| SCHEMBL24327737 | 0.78 | PPARG (0.49) | KMT2AMEN1LMNAPOLBBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| US-20220354809-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2022-11-10 | — | — | US | disclosed |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2022-02-03 | — | — | US | disclosed |
| US-11046641-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2021-06-29 | — | — | US | disclosed |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LTD (IE) | 2021-04-22 | — | — | US | disclosed |
| US-10959970-B2 | Methods of treating hair related conditions | NOGRA PHARMA LIMITED (IE) | 2021-03-30 | — | — | US | disclosed |
| US-20200383942-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| US-20200188340-A1 | Methods of Treating Hair Related Conditions | GIULIANI INTERNATIONAL, LTD. (IE) | 2020-06-18 | — | — | US | disclosed |
| US-20190269637-A1 | Alkylamido Compounds and Uses Thereof | GIULIANI INTERNATIONAL, LTD. (IE) | 2019-09-05 | — | — | US | disclosed |
| US-20120053245-A1 | Methods of Treating Hair Related Conditions | GIULIANI INTERNATIONAL, LTD. (IE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053245-A1 | Methods of Treating Hair Related Conditions | GIULIANI INTERNATIONAL, LTD. (IE) | 2012-03-01 | — | — | US | disclosed |
| CN-102020577-A | Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field | GIULIANI INT LTD | 2011-04-20 | — | — | CN | disclosed |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2009-02-19 | — | — | US | disclosed |
| CN-101243039-A | PPAR receptor and EGF receptor specific compounds and salts thereof and their use in the medical field | GIULIANI INT LTD (IE) | 2008-08-13 | — | — | CN | disclosed |
| EP-1910270-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | Giuliani International Limited (IE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010516-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007010516-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354809-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | KMT2A 4005/4885MEN1 4515/4885TDP1 3825/4885 |
| US-20190269637-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | KMT2A 4005/4885MEN1 4515/4885TDP1 3825/4885 |
| US-20200383942-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | KMT2A 4005/4885MEN1 4515/4885TDP1 3825/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | KMT2A 3951/4885MEN1 4490/4885TDP1 4088/4885 |
| US-20120053245-A1 | Methods of Treating Hair Related Conditions | PPARA, PPARG, PPARD | KMT2A 2859/4885MEN1 4764/4885TDP1 3941/4885 |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | EBP, AADAT, ALDH7A1 | KMT2A 2183/4885MEN1 4197/4885TDP1 3573/4885 |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | EGFR, ERBB3, FGFR3 | KMT2A 4180/4885MEN1 4017/4885TDP1 4879/4885 |
| US-10959970-B2 | Methods of treating hair related conditions | PPARA, PPARG, PPARD | KMT2A 2859/4885MEN1 4764/4885TDP1 3941/4885 |
| US-20200188340-A1 | Methods of Treating Hair Related Conditions | PPARA, PPARG, PPARD | KMT2A 2859/4885MEN1 4764/4885TDP1 3941/4885 |
| US-11046641-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | KMT2A 3951/4885MEN1 4490/4885TDP1 4088/4885 |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | KMT2A 3951/4885MEN1 4490/4885TDP1 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.